Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.67 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.67 |
| ▸ | CPT1A | P50416 | 12/20 | 0.66 |
| ▸ | CPT1B | Q92523 | 11/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CPT2 | P23786 | 7/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570373 | 0.94 | AKR1C3 (0.67) | AKR1C3AKR1C1CPT1ACPT1BMAPT | |
| SCHEMBL3572213 | 0.87 | AKR1C3 (0.72) | AKR1C3AKR1C1CASP3SENP8SENP7 | |
| SCHEMBL2898573 | 0.86 | CPT1A (0.62) | AKR1C3AKR1C1CPT1ACPT1BMAPT | |
| SCHEMBL30014628 | 0.83 | CPT1A (0.74) | CPT1ACPT1BMAPTCPT2 | |
| SCHEMBL3567632 | 0.83 | CPT1A (0.74) | CPT1ACPT1BMAPTCPT2 | |
| SCHEMBL665548 | 0.83 | AKR1C3 (0.74) | AKR1C3AKR1C1MAPTCASP3SENP8 | |
| SCHEMBL30015320 | 0.82 | CPT1A (0.85) | CPT1ACPT1BMAPTCPT2CASP3 | |
| SCHEMBL3579234 | 0.82 | CPT1A (0.85) | CPT1ACPT1BMAPTCPT2CASP3 | |
| SCHEMBL28775512 | 0.82 | CPT1A (0.64) | AKR1C3AKR1C1CPT1ACPT1BMAPT | |
| SCHEMBL3569896 | 0.81 | CPT1A (0.80) | CPT1ACPT1BMAPTCPT2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | claimed |
| CN-101263116-A | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | claimed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | claimed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | claimed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | claimed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| CN-101263116-B | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMAN-LA ROCHE LTD. (CH) | 2011-12-07 | — | — | CN | disclosed |
| US-7799933-B2 | Sulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2097373-B1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2097373-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| CN-101263116-A | Novel heterobicyclic derivatives useful as liver carnitine palmitoyl transferase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-09-10 | — | — | CN | disclosed |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008074692-A1 | SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | AKR1C3 281/4885AKR1C1 122/4885CPT1A 1/4885 |
| US-20080153805-A1 | SULFONAMIDE DERIVATIVES | CPT1A, SULT2A1, SULT1A1 | AKR1C3 375/4885AKR1C1 181/4885CPT1A 1/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | AKR1C3 2151/4885AKR1C1 1975/4885CPT1A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.